MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for its use in potentially transformative gene therapies.   “We look forward to collaborating with bluebird bio to bring to market breakthrough therapies to fight diseases for which there are limited or no options,” said Udit Batra, chief executive officer of MilliporeSigma. “With 30 years’ experience in viral vector manufacturing, we remain committed to innovatin...